Japan's Pharmaceuticals and Medical Devices Agency (PMDA) issued a Blue Letter warning to health care professionals about the possibility of interstitial lung disease in patients treated with Indianapolis-based Eli Lilly and Co.'s breast cancer drug, Verzenio (abemaciclib).